Kidney failure after treatment with 90Y-DOTATOC.
- 21 December 2001
- journal article
- letter
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 29 (3) , 435
- https://doi.org/10.1007/s00259-001-0720-2
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidneyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- End-stage renal disease after treatment with 90 Y-DOTATOCEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapyAmerican Journal of Kidney Diseases, 2001
- Yttrium-90 DOTATOC: first clinical resultsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations.European Journal of Nuclear Medicine and Molecular Imaging, 1998
- D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.1997
- Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.1995
- Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogueBritish Journal of Cancer, 1993